IUGNF (Imugene) Margin of Safety % (DCF Dividends Based): N/A (As of Jun. 30, 2026)


IUGNF Imugene Ltd IUGNF
30 GF Score
Price $0.08
! 4 Warning Signs
View Full Analysis

What is Imugene Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Imugene's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

IUGNF vs VRTX, REGN, ALNY: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Imugene's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Imugene Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imugene's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Imugene's Margin of Safety % (DCF Dividends Based) falls into.


IUGNF
30GF Score
Imugene Ltd IUGNF
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Imugene Business Description

Other Exchanges ILA:GermanyIMU:Australia
Address 4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
30GF Score

Get the complete analysis for IUGNF

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price